Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...1011121314151617181920...7475»
  • ||||||||||  Retrospective data, Review:  Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis. (Pubmed Central) -  Jul 13, 2022   
    We included RCTs of anti-VEGF drugs (intravitreal aflibercept (IVT-AFL), intravitreal ranibizumab (IVR), and intravitreal conbercept (IVC)) treating adult patients who were diagnosed with DME, regardless of stage or duration of the disease...The effect of improvement in BCVA was identified for IVT-AFL compared to intravitreal bevacizumab...After two years, there was insufficient evidence to identify which anti-VEGF has superior efficacy or safety. Clinical Trial Registration: https://www.crd.york.ac.uk/prospero/, PROSPERO; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021259335, CRD42021259335.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Journal:  Risk of dialysis in patients receiving intravitreal anti-vascular endothelial growth factor treatment: a population-based cohort study. (Pubmed Central) -  Jul 10, 2022   
    Patients newly receiving intravitreal ranibizumab or aflibercept from 2000 to 2017 for age-related macular degeneration, polypoidal choroidal vasculopathy, diabetic macular edema, retinal vein occlusions, or myopic choroid neovascularization were included as the study group, and patients with same retinal diseases but did not receive intravitreal anti-VEGFs served as controls extracted by age- and sex-matched (1:4) and further propensity score matching (PSM)...For subgroup analysis, patients newly receiving anti-VEGF treatment for diabetic macular edema had significant risk (adjusted HR: 1.834; 95% CI: 1.448-2.324) of becoming dialysis-dependent, while patients in other subgroups demonstrated similar risks as the controls. In conclusion, intravitreal anti-VEGF agents might increase the risk of becoming dialysis-dependent, especially in patients who are treated for diabetic macular edema.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Observational data, Retrospective data, Journal:  Long term results of three anti-vascular endothelial growth factor agents in pachychoroid neovasculopathy. (Pubmed Central) -  Jul 6, 2022   
    This is a retrospective, observational, comparative study that included 76 PNV eyes in 76 patients that were allocated to three groups according to the monotherapy injection procedure, as follows: the intravitreal bevacizumab (IVB) group, intravitreal ranibizumab (IVR) group, and intravitreal aflibercept (IVA) group...Patients treated with IVA required fewer injections than those treated with IVB or IVR. Furthermore, IVR and IVA treatment significantly decreased SFCT, whereas IVB did not.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  One-Month Outcomes of Intravitreal Anti-VEGF vs. Dexamethasone Implant in the Treatment of Diabetic Macular Edema in Vitrectomized Eyes. (Pubmed Central) -  Jul 2, 2022   
    To compare short-term effect of intravitreal ranibizumab with dexamethasone implant for diabetic macular edema (DME) in vitrectomized eyes...The changes of BCVA and CRT were significantly higher in IVD group than IVV group at Month1, but the changes were not significant at Week1. Comparing to anti-VEGF therapy, DEX implant is more effect in improving BCVA and reducing CRT in vitrectomized eyes at 1 month, which indicated DEX implant is a better strategy.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Journal:  Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study. (Pubmed Central) -  Jun 23, 2022   
    Treatment with 0.3 mg ranibizumab can reduce the recurrence rate of ROP without prolonging retinal vascularization or causing serious systemic complications. Therefore, this dose may be an appropriate therapeutic dose for ROP.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Correlation of Optical Coherence Tomography Angiography of Type 3 Macular Neovascularization With Corresponding Histology. (Pubmed Central) -  Jun 22, 2022   
    A White woman in her 90s with type 3 neovascularization secondary to age-related macular degeneration was treated with 37 intravitreal injections of ranibizumab and aflibercept in the right eye...OCTA decorrelation signal of type 3 neovascularization corresponded with intraretinal neovessels on histology. Projection artifact removal based on 2-dimensional vessel-shape estimation and Gaussian blur filter demonstrated their potential value for further use in OCTA decorrelation signal processing.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, Macugen (pegaptanib) / Bausch Health
    Journal:  Rapidly dissolving bilayer microneedles enabling minimally invasive and efficient protein delivery to the posterior segment of the eye. (Pubmed Central) -  Jun 22, 2022   
    Furthermore, ex vivo permeation studies showed that optimised MNs could permeate 86.99 ± 7.37% of OVA through the sclera, twice that of the needle-free patch (42.16 ± 3.95%), highlighting the capability of MNs to circumvent physical barriers and promote protein delivery to the posterior segment of the eye. In this work, a novel, efficient and safe intraocular protein delivery system was successfully established.
  • ||||||||||  CMAB818 (ranibizumab biosimilar) / 3SBio
    Trial completion date, Trial primary completion date:  Phase I Study to Compare CMAB818 Injection and Lucentis (clinicaltrials.gov) -  Jun 16, 2022   
    P1,  N=24, Recruiting, 
    IVR treatment may protect against PDR by promoting SPP1 expression through "GnRH secretion" and "Circadian rhythm" signaling pathway. Trial completion date: Jul 2022 --> May 2023 | Trial primary completion date: Feb 2022 --> Dec 2022
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema. (Pubmed Central) -  Jun 8, 2022   
    The data suggested that P. pastoris could be considered a potential efficient eukaryotic host for ranibizumab production. These findings suggest that IRI improves macular sensitivity in patients with CRVO and macular edema independent of any improvement in BCVA and that macular sensitivity before treatment is associated with improvement of macular sensitivity after treatment.
  • ||||||||||  Triesence (triamcinolone acetonide injectable suspension) / Novartis, Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
    Trial completion date, Trial primary completion date, Monotherapy:  Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (clinicaltrials.gov) -  Jun 1, 2022   
    P4,  N=150, Not yet recruiting, 
    But it caused more serious ocular adverse events which is worthy of special attention by ophthalmologists. Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: May 2023 --> Aug 2023
  • ||||||||||  Beovu (brolucizumab-dbll) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
    Biomarker, Review, Journal:  Biomarkers as Predictive Factors of Anti-VEGF Response. (Pubmed Central) -  May 30, 2022   
    The knowledge of how a patient will respond or how frequently retreatment might be required would be vital in planning treatment schedules, saving both resource utilization and financial costs, but today, there is not an ideal biomarker to use as a predictive response to ranibizumab therapy...Moreover, the great majority of studies carried out to date were focused on the search for SNPs in genes related to AMD risk factors, but miRNAs, proteomic and metabolomics studies have rarely been conducted in anti-VEGF-treated samples. Here, we propose that genomic, proteomic and/or metabolomic markers could be used not alone but in combination with other methods, such as specific clinic characteristics, to identify patients with a poor response to anti-VEGF treatment to establish patient-specific treatment plans.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Low-dose ranibizumab administration in retinopathy of prematurity. (Pubmed Central) -  May 26, 2022   
    Low-dose intravitreal ranibizumab injection with close follow-up and appropriate timing is an effective treatment modality in A-ROP. Even among patients undergoing rescue laser treatment, the treatment can be completed with a wide visual field.
  • ||||||||||  Susvimo (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Preclinical, Journal:  In-vitro characterization of ranibizumab release from the Port Delivery System. (Pubmed Central) -  May 26, 2022   
    P2, P3
    In conclusion, in-vitro studies were a powerful tool for characterizing and verifying ranibizumab release from the PDS implant and supported clinical evaluation of the PDS. PDS 100 mg/mL, which was associated with the longest therapeutic-level delivery of ranibizumab among the concentrations tested, was selected for evaluation in the pivotal phase III Archway trial.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  Bibliometric and visualized analysis of ocular drug delivery from 2001 to 2020. (Pubmed Central) -  May 26, 2022   
    The present study sheds light on current trends, global collaboration patterns, basic knowledge, research hotspots, and emerging frontiers of ocular drug delivery. Novel solutions for ocular drug delivery and the treatment of inflammation and posterior diseases were the major themes over the last 20 years.